NCT00022048View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2001

Study Completion Date

November 30, 2004

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

bevacizumab

Trial Locations (3)

85724

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson

94305-5750

Stanford Cancer Center at Stanford University Medical Center, Stanford

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT00022048 - Bevacizumab in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter